Leuco-Scint

Exametazime, the active ingredient in Leuco-Scint, is a radiopharmaceutical presented as a lyophilized kit for intravenous use. It is employed for cerebral perfusion imaging to assess regional blood flow in the brain, aiding diagnosis of stroke, dementia, epilepsy and brain tumors.

GNH USA supplies Leuco-Scint as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide.

Leuco-Scint (exametazime) is employed in cerebral perfusion imaging to evaluate regional blood flow in various neurological conditions. - Stroke: provides quantitative SPECT images of cerebral blood flow to identify ischemic regions. - Dementia: assists in differentiating Alzheimer’s disease from other dementias by mapping perfusion deficits. - Epilepsy: helps localize seizure foci through perfusion patterns during interictal periods. - Brain tumors: evaluates tumor vascularity and distinguishes tumor recurrence from treatment effects. - Cerebrovascular disease: assesses hemodynamic impact of arterial stenosis or occlusion.

Adverse reactions to Leuco-Scint are generally related to the radiopharmaceutical nature of the preparation and the intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache following injection. - Flushing: temporary reddening of skin. - Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure post‑administration. - Radiation‑induced skin injury: localized erythema at injection site. - Hemolysis: destruction of red blood cells, rare but serious.

When using Leuco-Scint, several precautions should be observed to ensure patient safety and product integrity. - Patient screening: assess for known hypersensitivity to technetium‑99m compounds. - Renal function: evaluate kidney status as impaired clearance may affect radiotracer distribution. - Pregnancy: avoid use unless clearly justified, due to fetal radiation exposure. - Medication review: inform clinicians of concurrent drugs that may alter cerebral blood flow. - Radiation safety: follow institutional protocols for handling and disposal of radioactive material. - Store at ambient temperature: keep kit in original packaging, protect from moisture and light, and use before expiry date.

Leuco-Scint may interact with other agents that influence cerebral blood flow or radiation handling.

Major Interactions (Avoid): - Vasodilators: concurrent strong vasodilators can alter tracer distribution, compromising image interpretation. - High‑dose steroids: may affect blood‑brain barrier permeability, leading to inaccurate perfusion assessment.

Moderate Interactions (Monitor Closely): - Anticonvulsants: some agents may modify cerebral metabolism, requiring careful timing of imaging. - Beta‑blockers: can reduce cerebral blood flow, potentially affecting tracer uptake. - Contrast agents: recent iodinated contrast may interfere with SPECT imaging quality.